Antibe Therapeutics Inc.

TSX:ATE Stock Report

Market Cap: CA$15.6m

Antibe Therapeutics Management

Management criteria checks 2/4

Antibe Therapeutics' CEO is Dan Legault, appointed in May 2009, has a tenure of 14.92 years. total yearly compensation is CA$784.86K, comprised of 65.6% salary and 34.4% bonuses, including company stock and options. directly owns 2.13% of the company’s shares, worth CA$333.17K. The average tenure of the management team and the board of directors is 4 years and 11.2 years respectively.

Key information

Dan Legault

Chief executive officer

CA$784.9k

Total compensation

CEO salary percentage65.6%
CEO tenure14.9yrs
CEO ownership2.1%
Management average tenure4yrs
Board average tenure11.2yrs

Recent management updates

Recent updates

Is Antibe Therapeutics (TSE:ATE) In A Good Position To Invest In Growth?

Dec 15
Is Antibe Therapeutics (TSE:ATE) In A Good Position To Invest In Growth?

We Think Antibe Therapeutics (TSE:ATE) Needs To Drive Business Growth Carefully

Mar 20
We Think Antibe Therapeutics (TSE:ATE) Needs To Drive Business Growth Carefully

Antibe Therapeutics (TSE:ATE) Is In A Strong Position To Grow Its Business

Oct 16
Antibe Therapeutics (TSE:ATE) Is In A Strong Position To Grow Its Business

Antibe Therapeutics Inc.'s (TSE:ATE) Profit Outlook

Feb 11
Antibe Therapeutics Inc.'s (TSE:ATE) Profit Outlook

We're Keeping An Eye On Antibe Therapeutics' (TSE:ATE) Cash Burn Rate

Jan 07
We're Keeping An Eye On Antibe Therapeutics' (TSE:ATE) Cash Burn Rate

Auditors Are Concerned About Antibe Therapeutics (CVE:ATE)

Jul 31
Auditors Are Concerned About Antibe Therapeutics (CVE:ATE)

Need To Know: The Consensus Just Cut Its Antibe Therapeutics Inc. (CVE:ATE) Estimates For 2021

Jul 29
Need To Know: The Consensus Just Cut Its Antibe Therapeutics Inc. (CVE:ATE) Estimates For 2021

CEO Compensation Analysis

How has Dan Legault's remuneration changed compared to Antibe Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-CA$18m

Sep 30 2023n/an/a

-CA$18m

Jun 30 2023n/an/a

-CA$19m

Mar 31 2023CA$785kCA$515k

-CA$19m

Dec 31 2022n/an/a

-CA$21m

Sep 30 2022n/an/a

-CA$22m

Jun 30 2022n/an/a

-CA$24m

Mar 31 2022CA$715kCA$443k

-CA$25m

Dec 31 2021n/an/a

-CA$26m

Sep 30 2021n/an/a

-CA$26m

Jun 30 2021n/an/a

-CA$25m

Mar 31 2021CA$3mCA$357k

-CA$24m

Dec 31 2020n/an/a

-CA$25m

Sep 30 2020n/an/a

-CA$23m

Jun 30 2020n/an/a

-CA$21m

Mar 31 2020CA$1mCA$311k

-CA$19m

Dec 31 2019n/an/a

-CA$17m

Sep 30 2019n/an/a

-CA$16m

Jun 30 2019n/an/a

-CA$13m

Mar 31 2019CA$2mCA$311k

-CA$13m

Dec 31 2018n/an/a

-CA$11m

Sep 30 2018n/an/a

-CA$9m

Jun 30 2018n/an/a

-CA$8m

Mar 31 2018CA$273kCA$273k

-CA$7m

Compensation vs Market: Dan's total compensation ($USD572.79K) is above average for companies of similar size in the Canadian market ($USD174.55K).

Compensation vs Earnings: Dan's compensation has increased whilst the company is unprofitable.

CEO

Dan Legault (65 yo)

14.9yrs

Tenure

CA$784,861

Compensation

Mr. Daniel Marcel Legault, also known as Dan, J.D., L.L.B, served as the Independent Chairman at Klinik Health Ventures Corp. and served as its Independent Director since April 17, 2019 and served as its P...

Leadership Team

NamePositionTenureCompensationOwnership
Daniel Legault
President14.9yrsCA$784.86k2.13%
CA$ 333.2k
Alain Wilson
Chief Financial Officer8.3yrsCA$219.93k0.13%
CA$ 20.3k
Scott Curtis
Chief Operating Officer1.7yrsCA$316.21k0.22%
CA$ 33.9k
David Vaughan
Chief Development Officerno dataCA$423.61k0.050%
CA$ 7.9k
Joseph Stauffer
Chief Medical Officer4yrsCA$1.13m0.48%
CA$ 75.2k
Ana Stegic
Executive Director of Clinical Operations2.9yrsCA$263.34k0.079%
CA$ 12.3k
Christina Cameron
Vice President of Investor Relationsno datano datano data
Philip Stern
Vice President of Communicationsno datano datano data

4.0yrs

Average Tenure

65yo

Average Age

Experienced Management: ATE's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Daniel Legault
President14.9yrsCA$784.86k2.13%
CA$ 333.2k
Robert Hoffman
Independent Chair of the Board3.4yrsCA$78.61k0.072%
CA$ 11.3k
Louis Ignarro
Member of Scientific Advisory Boardno datano datano data
Roderick Flower
Independent Director11.2yrsCA$64.03k0.35%
CA$ 54.6k
Walter MacNee
Independent Vice Chair11.2yrsCA$58.20k0.95%
CA$ 148.2k
Andre Buret
Member of Scientific Advisory Boardno datano datano data
Daniel Podolsky
Member of Scientific Advisory Boardno datano datano data
Giuseppe Cirino
Member of Scientific Advisory Boardno datano datano data
Peter Ernst
Member of Scientific Advisory Boardno datano datano data
Richard Hunt
Member of Scientific Advisory Boardno datano datano data
Gilberto de Nucci
Member of Scientific Advisory Boardno datano datano data
William Sessa
Member of Scientific Advisory Boardno datano datano data

11.2yrs

Average Tenure

69yo

Average Age

Experienced Board: ATE's board of directors are seasoned and experienced ( 11.2 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.